Here are the 10-Q quarterly reports from Drugs Made In America Acquisition Corp. Rights (DMAAR) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow DMAAR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DMAAR filings page.
Drugs Made In America Acquisition Corp., a Cayman Islands SPAC, reported June 30, 2026 assets of $146.9 million, including $146.8 million of cash and investments in its Trust Account and $20,280 of operating cash. Ordinary shares subject to possible redemption totaled 13,559,770 with a redemption value of $145.2 million.
During the April 27, 2026 extension vote, holders of 9,440,230 shares redeemed for $99.3 million (about $10.52 per share), significantly reducing the Trust balance. An investor deposited $600,000 via Extension Advance Notes by June 30, 2026 to extend the combination deadline, with an additional $300,000 deposited on July 27, 2026. Net income was $3.7 million for the six months, driven by $4.0 million of interest on Trust investments and low operating costs. The company entered into a Definitive Merger Agreement with PAGC on April 29, 2026. Management discloses a working capital deficit of $2.9 million and states that the mandatory liquidation date and funding needs raise substantial doubt about its ability to continue as a going concern absent completion of a Business Combination within the extended period.
Drugs Made In America Acquisition Corp. reported Q1 2026 net income of $1.97 million, driven by $2.11 million of interest on its $242.0 million trust account and modest general and administrative costs of $143,301.
The SPAC remains pre‑revenue, with cash of $14,887 and a working capital deficit of $477,282, and its auditors highlight substantial doubt about its ability to continue as a going concern without completing a business combination. In April 2026, shareholders approved an extension of the combination deadline to as late as April 29, 2027, with redemptions of 9,440,230 shares for about $99.3 million, leaving 24,276,913 ordinary shares outstanding. The company also signed an interim $100,000 convertible note and a definitive merger agreement with Power Analytics Global Corp., positioning that business as the intended operating company after the de‑SPAC transaction.